Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016, Article ID 6143129, 12 pages
http://dx.doi.org/10.1155/2016/6143129
Review Article

Subclinical Detection of Diabetic Cardiomyopathy with MicroRNAs: Challenges and Perspectives

1Centro de Genética y Genómica, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, 7710162 Santiago, Chile
2Regenerative Medicine Institute (REMEDI), National University of Ireland, Galway, Ireland
3Clínica Alemana, 7650568 Santiago, Chile
4Centro de Medicina Regenerativa, Facultad de Medicina, Clínica Alemana-Universidad del Desarrollo, 7710162 Santiago, Chile

Received 1 June 2015; Revised 17 July 2015; Accepted 26 July 2015

Academic Editor: Dirk Westermann

Copyright © 2016 Luis E. León et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. IDF, IDF Diabetes Atlas, International Diabetes Federation, Brussels, Belgium, 6th edition, 2014.
  2. M. C. Blendea, S. I. McFarlane, E. R. Isenovic, G. Gick, and J. R. Sowers, “Heart disease in diabetic patients,” Current Diabetes Reports, vol. 3, no. 3, pp. 223–229, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. A. I. Vinik and D. Ziegler, “Diabetic cardiovascular autonomic neuropathy,” Circulation, vol. 115, no. 3, pp. 387–397, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Bugger and C. Bode, “The vulnerable myocardium. Diabetic cardiomyopathy,” Hämostaseologie, vol. 35, no. 1, pp. 17–24, 2015. View at Publisher · View at Google Scholar
  5. A. M. From, C. L. Leibson, F. Bursi et al., “Diabetes in heart failure: prevalence and impact on outcome in the population,” The American Journal of Medicine, vol. 119, no. 7, pp. 591–599, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. A. M. Shah, H. Uno, L. Køber et al., “The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction,” European Journal of Heart Failure, vol. 12, no. 11, pp. 1229–1237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Rubler, J. Dlugash, Y. Z. Yuceoglu, T. Kumral, A. W. Branwood, and A. Grishman, “New type of cardiomyopathy associated with diabetic glomerulosclerosis,” The American Journal of Cardiology, vol. 30, no. 6, pp. 595–602, 1972. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Bugger and E. D. Abel, “Rodent models of diabetic cardiomyopathy,” Disease Models & Mechanisms, vol. 2, no. 9-10, pp. 454–466, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Bugger and E. D. Abel, “Molecular mechanisms of diabetic cardiomyopathy,” Diabetologia, vol. 57, no. 4, pp. 660–671, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Miki, S. Yuda, H. Kouzu, and T. Miura, “Diabetic cardiomyopathy: pathophysiology and clinical features,” Heart Failure Reviews, vol. 18, no. 2, pp. 149–166, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Dei Cas, V. Spigoni, V. Ridolfi, and M. Metra, “Diabetes and chronic heart failure: from diabetic cardiomyopathy to therapeutic approach,” Endocrine, Metabolic & Immune Disorders—Drug Targets, vol. 13, no. 1, pp. 38–50, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Boudina and E. D. Abel, “Diabetic cardiomyopathy, causes and effects,” Reviews in Endocrine & Metabolic Disorders, vol. 11, no. 1, pp. 31–39, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Chavali, S. C. Tyagi, and P. K. Mishra, “Predictors and prevention of diabetic cardiomyopathy,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 6, pp. 151–160, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Teupe and C. Rosak, “Diabetic cardiomyopathy and diastolic heart failure—difficulties with relaxation,” Diabetes Research and Clinical Practice, vol. 97, no. 2, pp. 185–194, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. J.-W. Ha, H.-C. Lee, E.-S. Kang et al., “Abnormal left ventricular longitudinal functional reserve in patients with diabetes mellitus: implication for detecting subclinical myocardial dysfunction using exercise tissue Doppler echocardiography,” Heart, vol. 93, no. 12, pp. 1571–1576, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. J. M. McGavock, I. Lingvay, I. Zib et al., “Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study,” Circulation, vol. 116, no. 10, pp. 1170–1175, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Shah, B. G. Choi, and R. Mazhari, “Positron emission tomography for the evaluation and treatment of cardiomyopathy,” Annals of the New York Academy of Sciences, vol. 1228, no. 1, pp. 137–149, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Romano, M. Di Mauro, S. Fratini et al., “Early diagnosis of left ventricular diastolic dysfunction in diabetic patients: a possible role for natriuretic peptides,” Cardiovascular Diabetology, vol. 9, article 89, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Rahimi, D. Bennett, N. Conrad et al., “Risk prediction in patients with heart failure: a systematic review and analysis,” JACC: Heart Failure, vol. 2, no. 5, pp. 440–446, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Palazzuoli, S. Masson, C. Ronco, and A. Maisel, “Clinical relevance of biomarkers in heart failure and cardiorenal syndrome: the role of natriuretic peptides and troponin,” Heart Failure Reviews, vol. 19, no. 2, pp. 267–284, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. E. C. Lai, “Two decades of miRNA biology: lessons and challenges,” RNA, vol. 21, no. 4, pp. 675–677, 2015. View at Publisher · View at Google Scholar
  22. M. Asrih and S. Steffens, “Emerging role of epigenetics and miRNA in diabetic cardiomyopathy,” Cardiovascular Pathology, vol. 22, no. 2, pp. 117–125, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. V. K. Cortessis, D. C. Thomas, A. Joan Levine et al., “Environmental epigenetics: prospects for studying epigenetic mediation of exposure-response relationships,” Human Genetics, vol. 131, no. 10, pp. 1565–1589, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. V. Ambros, “The functions of animal microRNAs,” Nature, vol. 431, no. 7006, pp. 350–355, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. W. Filipowicz, S. N. Bhattacharyya, and N. Sonenberg, “Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?” Nature Reviews Genetics, vol. 9, no. 2, pp. 102–114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Lu, R. J. Buchan, and S. A. Cook, “MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism,” Cardiovascular Research, vol. 86, no. 3, pp. 410–420, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. H. El Azzouzi, S. Leptidis, E. Dirkx et al., “The hypoxia-inducible microRNA cluster miR-199a approximately 214 targets myocardial PPARdelta and impairs mitochondrial fatty acid oxidation,” Cell Metabolism, vol. 18, no. 3, pp. 341–354, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. Duan, B. Zhou, H. Su, Y. Liu, and C. Du, “MiR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300,” Experimental Cell Research, vol. 319, no. 3, pp. 173–184, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. B. Feng, S. Chen, B. George, Q. Feng, and S. Chakrabarti, “miR133a regulates cardiomyocyte hypertrophy in diabetes,” Diabetes/Metabolism Research and Reviews, vol. 26, no. 1, pp. 40–49, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. E. Shen, X. Diao, X. Wang, R. Chen, and B. Hu, “MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy,” The American Journal of Pathology, vol. 179, no. 2, pp. 639–650, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. X. Diao, E. Shen, X. Wang, and B. Hu, “Differentially expressed microRNAs and their target genes in the hearts of streptozotocin-induced diabetic mice,” Molecular Medicine Reports, vol. 4, no. 4, pp. 633–640, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. F. Zhao, B. Li, Y.-Z. Wei et al., “MicroRNA-34a regulates high glucose-induced apoptosis in H9c2 cardiomyocytes,” Journal of Huazhong University of Science and Technology—Medical Science, vol. 33, no. 6, pp. 834–839, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. X.-Y. Yu, Y.-H. Song, Y.-J. Geng et al., “Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1,” Biochemical and Biophysical Research Communications, vol. 376, no. 3, pp. 548–552, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. S. S. Yildirim, D. Akman, D. Catalucci, and B. Turan, “Relationship between downregulation of miRNAs and increase of oxidative stress in the development of diabetic cardiac dysfunction: junctin as a target protein of miR-1,” Cell Biochemistry and Biophysics, vol. 67, no. 3, pp. 1397–1408, 2013. View at Publisher · View at Google Scholar · View at Scopus
  35. X. Li, N. Du, Q. Zhang et al., “MicroRNA-30d regulates cardiomyocyte pyroptosis by directly targeting foxo3a in diabetic cardiomyopathy,” Cell Death and Disease, vol. 5, article e1479, 2014. View at Publisher · View at Google Scholar
  36. X. H. Wang, R. Z. Qian, W. Zhang, S. F. Chen, H. M. Jin, and R. M. Hu, “MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats,” Clinical and Experimental Pharmacology and Physiology, vol. 36, no. 2, pp. 181–188, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. S. K. Panguluri, J. Tur, K. C. Chapalamadugu, C. Katnik, J. Cuevas, and S. M. Tipparaju, “MicroRNA-301a mediated regulation of Kv4.2 in diabetes: identification of key modulators,” PLoS ONE, vol. 8, no. 4, article e60545, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. W. A. Baseler, D. Thapa, R. Jagannathan, E. R. Dabkowski, T. L. Croston, and J. M. Hollander, “miR-141 as a regulator of the mitochondrial phosphate carrier (Slc25a3) in the type 1 diabetic heart,” The American Journal of Physiology—Cell Physiology, vol. 303, no. 12, pp. C1244–C1251, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Kuwabara, T. Horie, O. Baba et al., “MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway,” Circulation Research, vol. 116, no. 2, pp. 279–288, 2015. View at Publisher · View at Google Scholar · View at Scopus
  40. S. Ong and J. C. Wu, “Exosomes as potential alternatives to stem cell therapy in mediating cardiac regeneration,” Circulation Research, vol. 117, no. 1, pp. 7–9, 2015. View at Publisher · View at Google Scholar
  41. Z. A. Malik, K. S. Kott, A. J. Poe et al., “Cardiac myocyte exosomes: stability, HSP60, and proteomics,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 304, no. 7, pp. H954–H965, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. N. Gennebäck, U. Hellman, L. Malm et al., “Growth factor stimulation of cardiomyocytes induces changes in the transcriptional contents of secreted exosomes,” Journal of Extracellular Vesicles, vol. 2, 2013. View at Publisher · View at Google Scholar
  43. A. Waldenström, N. Gennebäck, U. Hellman, and G. Ronquist, “Cardiomyocyte microvesicles contain DNA/RNA and convey biological messages to target cells,” PLoS ONE, vol. 7, no. 4, Article ID e34653, 2012. View at Publisher · View at Google Scholar · View at Scopus
  44. C. Bang, S. Batkai, S. Dangwal et al., “Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy,” The Journal of Clinical Investigation, vol. 124, no. 5, pp. 2136–2146, 2014. View at Publisher · View at Google Scholar · View at Scopus
  45. S. Rani, “MicroRNA profiling of exosomes isolated from biofluids and conditioned media,” Methods in Molecular Biology, vol. 1182, pp. 131–144, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. K. C. Vickers, B. T. Palmisano, B. M. Shoucri, R. D. Shamburek, and A. T. Remaley, “MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins,” Nature Cell Biology, vol. 13, no. 4, pp. 423–435, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. F. Spillmann, S. van Linthout, and C. Tschöpe, “Cardiac effects of HDL and its components on diabetic cardiomyopathy,” Endocrine, Metabolic & Immune Disorders—Drug Targets, vol. 12, no. 2, pp. 132–147, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. J. F. Aranda, J. Madrigal-Matute, N. Rotllan, and C. Fernández-Hernando, “MicroRNA modulation of lipid metabolism and oxidative stress in cardiometabolic diseases,” Free Radical Biology and Medicine, vol. 64, pp. 31–39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. G. Meister, “Argonaute proteins: functional insights and emerging roles,” Nature Reviews Genetics, vol. 14, no. 7, pp. 447–459, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. J. D. Arroyo, J. R. Chevillet, E. M. Kroh et al., “Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 12, pp. 5003–5008, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. R. C. Friedman, K. K.-H. Farh, C. B. Burge, and D. P. Bartel, “Most mammalian mRNAs are conserved targets of microRNAs,” Genome Research, vol. 19, no. 1, pp. 92–105, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. J. P. Mehta, “Sequencing small RNA: introduction and data analysis fundamentals,” Methods in Molecular Biology, vol. 1182, pp. 93–103, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. P. Alexiou, M. Maragkakis, G. L. Papadopoulos, V. A. Simmosis, L. Zhang, and A. G. Hatzigeorgiou, “The DIANA-mirExTra web server: from gene expression data to microRNA function,” PLoS ONE, vol. 5, no. 2, Article ID e9171, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Kunz, K. Xiao, C. Liang et al., “Bioinformatics of cardiovascular miRNA biology,” Journal of Molecular and Cellular Cardiology, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. H. Dweep, C. Sticht, P. Pandey, and N. Gretz, “MiRWalk–database: prediction of possible miRNA binding sites by ‘walking’ the genes of three genomes,” Journal of Biomedical Informatics, vol. 44, no. 5, pp. 839–847, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. S. S. C. Chim, T. K. F. Shing, E. C. W. Hung et al., “Detection and characterization of placental microRNAs in maternal plasma,” Clinical Chemistry, vol. 54, no. 3, pp. 482–490, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. C. H. Lawrie, S. Gal, H. M. Dunlop et al., “Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma,” British Journal of Haematology, vol. 141, no. 5, pp. 672–675, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. M. A. Cortez and G. A. Calin, “MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases,” Expert Opinion on Biological Therapy, vol. 9, no. 6, pp. 703–711, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. S. P. Romaine, M. Tomaszewski, G. Condorelli, and N. J. Samani, “MicroRNAs in cardiovascular disease: an introduction for clinicians,” Heart, vol. 101, no. 12, pp. 921–928, 2015. View at Publisher · View at Google Scholar
  60. L. Tan, J.-T. Yu, and L. Tan, “Causes and consequences of microRNA dysregulation in neurodegenerative diseases,” Molecular Neurobiology, vol. 51, no. 3, pp. 1249–1262, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. G. S. Mack, “MicroRNA gets down to business,” Nature Biotechnology, vol. 25, no. 6, pp. 631–638, 2007. View at Publisher · View at Google Scholar · View at Scopus
  62. miRBase, 21st version, http://www.mirbase.org/.
  63. M. R. Friedländer, E. Lizano, A. J. S. Houben et al., “Evidence for the biogenesis of more than 1,000 novel human microRNAs,” Genome Biology, vol. 15, no. 4, article R57, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. C. C. Pritchard, H. H. Cheng, and M. Tewari, “MicroRNA profiling: approaches and considerations,” Nature Reviews Genetics, vol. 13, no. 5, pp. 358–369, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Zampetaki, S. Kiechl, I. Drozdov et al., “Plasma MicroRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes,” Circulation Research, vol. 107, no. 6, pp. 810–817, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. F. J. Ortega, J. M. Mercader, J. M. Moreno-Navarrete et al., “Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization,” Diabetes Care, vol. 37, no. 5, pp. 1375–1383, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. Liu, G. Gao, C. Yang et al., “The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus,” International Journal of Molecular Sciences, vol. 15, no. 6, pp. 10567–10577, 2014. View at Publisher · View at Google Scholar · View at Scopus
  68. D. S. Karolina, A. Armugam, S. Tavintharan et al., “MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus,” PLoS ONE, vol. 6, no. 8, Article ID e22839, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. N. Pescador, M. Pérez-Barba, J. M. Ibarra, A. Corbatón, M. T. Martínez-Larrad, and M. Serrano-Ríos, “Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers,” PLoS ONE, vol. 8, no. 10, Article ID e77251, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. X. Wang, J. Sundquist, B. Zöller et al., “Determination of 14 circulating microRNAs in Swedes and Iraqis with and without diabetes mellitus type 2,” PLoS ONE, vol. 9, no. 1, Article ID e86792, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. R. Bijkerk, J. M. Duijs, M. Khairoun et al., “Circulating MicroRNAs associate with diabetic nephropathy and systemic microvascular damage and normalize after simultaneous pancreas-kidney transplantation,” American Journal of Transplantation, vol. 15, no. 4, pp. 1081–1090, 2015. View at Publisher · View at Google Scholar
  72. M. A. Bellinger, J. S. Bean, M. A. Rader et al., “Concordant changes of plasma and kidney microRNA in the early stages of acute kidney injury: time course in a mouse model of bilateral renal ischemia-reperfusion,” PLoS ONE, vol. 9, no. 4, Article ID e93297, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. S. S. Acharya, W. Fendler, J. Watson et al., “Serum microRNAs are early indicators of survival after radiation-induced hematopoietic injury,” Science Translational Medicine, vol. 7, no. 287, Article ID 287ra269, 2015. View at Google Scholar
  74. P. Rotkrua, S. Shimada, K. Mogushi, Y. Akiyama, H. Tanaka, and Y. Yuasa, “Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model,” British Journal of Cancer, vol. 108, no. 4, pp. 932–940, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. S. D. Calligaris, M. Lecanda, F. Solis et al., “Mice long-term high-fat diet feeding recapitulates human cardiovascular alterations: an animal model to study the early phases of diabetic cardiomyopathy,” PLoS ONE, vol. 8, no. 4, Article ID e60931, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. L. Moldovan, K. E. Batte, J. Trgovcich, J. Wisler, C. B. Marsh, and M. Piper, “Methodological challenges in utilizing miRNAs as circulating biomarkers,” Journal of Cellular and Molecular Medicine, vol. 18, no. 3, pp. 371–390, 2014. View at Publisher · View at Google Scholar · View at Scopus
  77. B. Yang, H. Lin, J. Xiao et al., “The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2,” Nature Medicine, vol. 13, no. 4, pp. 486–491, 2007. View at Publisher · View at Google Scholar · View at Scopus
  78. J. Xiao, X. Luo, H. Lin et al., “MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts,” The Journal of Biological Chemistry, vol. 282, pp. 12363–12367, 2007. View at Publisher · View at Google Scholar
  79. L. Kong, J. Zhu, W. Han et al., “Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study,” Acta Diabetologica, vol. 48, no. 1, pp. 61–69, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. E. van Rooij, L. B. Sutherland, N. Liu et al., “A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 48, pp. 18255–18260, 2006. View at Publisher · View at Google Scholar · View at Scopus
  81. Z. Lu, Y. Li, A. Takwi et al., “miR-301a as an NF-kappaB activator in pancreatic cancer cells,” The EMBO Journal, vol. 30, no. 1, pp. 57–67, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. B. K. Panama, D. Latour-Villamil, G. P. Farman et al., “Nuclear factor κb downregulates the transient outward potassium current Ito,f through control of KChIP2 expression,” Circulation Research, vol. 108, no. 5, pp. 537–543, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. A. K. Pandey, P. Agarwal, K. Kaur, and M. Datta, “MicroRNAs in diabetes: tiny players in big disease,” Cellular Physiology and Biochemistry, vol. 23, no. 4–6, pp. 221–232, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Greco, P. Fasanaro, S. Castelvecchio et al., “MicroRNA dysregulation in diabetic ischemic heart failure patients,” Diabetes, vol. 61, no. 6, pp. 1633–1641, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. X. Zhong, A. C. K. Chung, H. Y. Chen et al., “MiR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes,” Diabetologia, vol. 56, no. 3, pp. 663–674, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. J. Osipova, D.-C. Fischer, S. Dangwal et al., “Diabetes-associated MicroRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study,” Journal of Clinical Endocrinology and Metabolism, vol. 99, no. 9, pp. E1661–E1665, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. C. Higuchi, A. Nakatsuka, J. Eguchi et al., “Identification of circulating miR-101, miR-375 and miR-802 as biomarkers for type 2 diabetes,” Metabolism, vol. 64, no. 4, pp. 489–497, 2015. View at Publisher · View at Google Scholar